[144] Nektar Therapeutics SEC Filing

Rhea-AI Filing Summary

Nektar Therapeutics (NKTR) filed a Form 144 notifying the proposed sale of 1,573 common shares acquired on 08/15/2025 through restricted stock vesting. The filer lists an aggregate market value of $41,826.23 for those shares and reports approximately 19,018,573 shares outstanding. The proposed sale date is 08/19/2025 on NASDAQ, and the securities were recorded as compensation. The filing also discloses that Howard Robin sold 23,208 common shares on 05/19/2025 for gross proceeds of $15,579.54. The notice includes the standard representation that the signer does not possess undisclosed material adverse information.

Positive

• Disclosure compliance: The filer submitted a Form 144 detailing the proposed sale and acquisition method, supporting regulatory transparency
• Acquisition via compensation: The 1,573 shares were acquired through restricted stock vesting, a common, non-market-price-based grant

Negative

• Insider sale: Howard Robin sold 23,208 shares on 05/19/2025, indicating recent insider liquidity
• Small aggregated market value relative to potential investor concern: The proposed sale value is $41,826.23, which may draw attention despite being modest

Insights

Securities Analyst

TL;DR: Insider issued and proposing sale are routine compensation-related and small relative to total shares outstanding.

The filing reports a restricted stock vesting of 1,573 shares converted to a proposed sale on 08/19/2025 with an aggregate market value of $41,826.23. Such Form 144 notices are procedural when insiders sell shares received as compensation; they provide transparency about timing and planned disposition. The prior sale by Howard Robin of 23,208 shares on 05/19/2025 is disclosed, showing recent insider liquidity. Based solely on the filing, these transactions are disclosed but do not, by themselves, indicate operational changes at the issuer.

Corporate Governance Expert

TL;DR: Filing documents compliance with Rule 144 and includes required insider certification; no undisclosed material facts asserted.

The notice includes the required certification that the seller is unaware of undisclosed material adverse information and documents the nature of acquisition as compensation. The combination of vesting-triggered shares and a recent separate sale by an individual insider is consistent with routine executive compensation and liquidity events. From a governance standpoint, timely disclosure via Form 144 meets regulatory transparency expectations.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	1573	41826.23	19018573	08/19/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/15/2025	Restricted Stock Vesting	Issuer			1573	08/15/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Howard Robin 455 Mission Bay Boulevard South San Francisco CA 94158	Common	05/19/2025	23208	15579.54

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed by NKTR disclose?

The Form 144 discloses a proposed sale of 1,573 common shares acquired on 08/15/2025 via restricted stock vesting, with an aggregate market value of $41,826.23 and an approximate sale date of 08/19/2025 on NASDAQ.

How many shares does Nektar report outstanding in the filing?

The filing reports approximately 19,018,573 shares outstanding.

Did any insider sell NKTR shares recently according to this filing?

Yes. The filing shows that Howard Robin sold 23,208 common shares on 05/19/2025 for gross proceeds of $15,579.54.

How were the 1,573 shares acquired?

The 1,573 shares were acquired on 08/15/2025 through restricted stock vesting and were recorded as compensation.

When is the proposed sale date and on which exchange will it occur?

The proposed sale is dated approximately 08/19/2025 and the filing lists NASDAQ as the exchange.